NV-BITSENSING
12.1.2021 13:02:35 CET | Business Wire | Press release
bitsensing , a South Korean radar technology startup, introduces the new mini Healthcare Radar, mini-H , the smallest high-resolution 60GHz IoT Radar sensor in the lineup. The innovation behind the mini-H demonstrates the company’s industry leading expertise in designing and building cutting edge radar technology that can transform healthcare, automotive, mobility, smart home, security, and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005325/en/
Dr. Jae-Eun Lee, CEO of bitsensing, a seasoned engineer in radar technology and formerly a part of the automotive world at Mando Corp., knows what it takes to create a safe and conveniently connected world. “Revolutionary technologies such as mini-H are propelling what is possible in all facets of our daily lives,” says Lee. “We at bitsensing are committed to integrating these groundbreaking radar technologies to help build smart lives and smart cities which ultimately elevates the quality of life for all.”
The advanced mini-H sensor attaches to the wall and can detect, in real-time, presence, movement, breathing or lack thereof, and falls by measuring breathing patterns and pulsating vessels without the use of intrusive cameras or wearables.
Specifically designed for a more intelligent and safer monitoring system for telehealth, mini-H can be used in dark or wet places and works regardless of clothes or blankets. The Bluetooth and WiFi communication module allows for a seamless transfer of data from the radar to dashboards or the app for easy tracking. This fully wireless product makes it quick and easy to implement software advancements, ensuring the product is always up to date. The sleek, compact aesthetic of the product also allows for an easy integration while the plug and play style provides instant monitoring of activities with the option to adjust settings for optimal personalization.
As a leading radar solution company, bitsensing offers complete end to end services, creating customizable radars like the mini-H that exceed industry standards in convenience and security. The nimble structure of bitsensing allows the team to deliver powerful products quickly while working directly with end customers across a large range of industries to ensure satisfaction and broaden their horizons of what is possible in a smart life.
CES attendees can visit bitsensing’s virtual booth to learn more about the mini-H from January 11-14, 2021. To view the mini-H informational product video, please visit here . If you are interested in learning more about our radar solution offerings, please visit www.bitsensing.com .
mini-H Product Specifications
Specs subject to change without notice. All functionality, features, specifications and other product information provided in this document including, but not limited to, the benefits, design, pricing, components, performance, availability, and capabilities of the product are subject to change without notice.
General Spec |
|
Centered Frequency |
61 GHz |
Bandwidth |
3.75 GHz |
Communication Interface |
WiFi or Bluetooth, RS485 |
Coverage Spec |
|
Detection Range |
0.2m ~ 2.5m |
Field of View |
±60° (Azimuth), ±60° (Elevation) |
Feature |
Moving, Falling, Presence, Apnea |
Vital Sign |
Respiration* |
Resolution |
0.04m |
Electrical Spec |
|
Operating Voltage |
7V ~ 14V |
Current Consumption |
Max 3W |
Mechanical Spec |
|
Dimensions |
50 x 50 x 15 mm |
Weight |
100g** |
Connector |
Open terminal Cable |
Environment Spec |
|
Operating Temperature |
-20 ~ +85 °C |
* The data driven by respiration detection may be limited and is designed to be used for apnea detection |
** The weight is without cable |
About bitsensing
bitsensing is an imaging radar technology company committed to building safer smart cities and elevating connected living by designing cutting-edge sensor fusions and AI solutions bringing an unprecedented level of intelligence to smart living. Founded in 2018 by seasoned automotive experts, bitsensing is one of the only startups delivering optimal technologies that meet and exceed the high level of safety and convenience that the industry demands. bitsensing is transforming possibilities to bring democratization of smart life in healthcare, automotive, mobility, smart home, security, and beyond.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom